Announcement on Passing On-site Inspection by FDA
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Passing On-site Inspection by FDA
Filed with SSE ·
6ix hasn’t read this filing yet.
Aurisco Pharmaceutical Co. Ltd. on 6ix
Earlier from Aurisco Pharmaceutical
- Announcement on Adjusting Upper Limit of Shares Repurchase Price after Implementing Dividend Distribution for 2024
- Announcement on Adjusting the Total Cash Dividends for Profit Distribution in 2024
- Indicative Announcement on Suspending Conversion of "Aurisco Convertible Bonds" during Implementation of Dividend Distribution for 2024
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Change in Bondholders' Holding Ratio of Convertible Bonds Reaching 10%
Later from Aurisco Pharmaceutical
- Announcement on 2025 Tracking Credit Rating Results of "Aurisco Convertible Bonds"
- Announcement on Interest Payment for "Aurisco Convertible Bonds" in 2025
- Announcement on Redemption upon Maturity of Partial Idle Raised Funds Used for Cash Management
- Announcement on Shareholding Reduction Plan for Partial Senior Executives
- Announcement on Convening the 2025 Semi-annual Performance Briefing
Follow Aurisco Pharmaceutical into a list and get an email when it puts out news.
Follow Aurisco Pharmaceutical